HTS Assays for Modulators of GPCR Signaling

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,372,970.00
Award Year:
2009
Program:
SBIR
Phase:
Phase II
Contract:
2R44NS059082-02
Award Id:
85927
Agency Tracking Number:
NS059082
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
5500 Nobel Drive, Suite 250, MADISON, WI, 53711
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
119165251
Principal Investigator:
ROBERT LOWERY
(608) 227-4501
BOB.LOWERY@BELLBROOKLABS.COM
Business Contact:
ROBERT LOWERY
() -
bob.lowery@bellbrooklabs.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): More than 50% of drugs on the market target G protein-coupled receptors (GPCRs). Among the most important of these are drugs used to treat neurological disorders, such as pain relievers, antidepressants and anti-psychot ics, as well drugs used for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. The relatively recent discovery of a family of proteins called regulator of G protein signaling (RGS), that attenuate GPCR signals by increasing t he GTPase activity of associated G proteins, has opened up a new avenue for modulating the activity of endogenous and administered GPCR ligands. However, development of inhibitors to RGS proteins has been hampered by the lack of robust assay methods for hi gh throughput screening (HTS). In Phase I we developed fluorescence based GDP detection assays to measure RGS-dependent increases in the steady state GTPase activity of modified G proteins. The G proteins were mutated to increase the rate of GDP dissociati on relative to GTP hydrolysis so that the GTPase accelerating activity of RGS proteins could be directly measured. These developments comprise the first HTS-compatible biochemical assay system for measuring RGS catalytic activity. In Phase II we will exten d the approach to additional RGS and G proteins, and use the novel molecular tools in combination with cheminformatics to develop RGS-selective small molecule inhibitors. The inhibitors will be characterized biochemically and there in a cellular context. T he availability of these novel HTS assays and inhibitors will accelerate drug discovery focused on RGS proteins and delineation of their roles in GPCR signal transduction. We will continue our successful collaboration with Dr. David Siderovski at the Depar tment of Pharmacology, University of North Carolina Medical School in Phase II. PUBLIC HEALTH RELEVANCE: Over half of current drugs exert their effects through a family of proteins called G protein- coupled receptors, and the targeting of these receptors h as been especially useful for the development of drugs used to treat neurological disorders such as schizophrenia, depression, and Parkinson's disease. To accelerate discovery of more selective therapies for these and other diseases, we are developing and validating novel screening assays for a family of proteins, called 'regulator of G-protein signaling' (RGS) that modulate the effects of GPCR ligands in a tissue-specific manner.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government